Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.45 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5730708 | 0.98 | LMNA (0.45) | PADI1PADI4HDAC8HDAC6LMNA | |
| SCHEMBL1953634 | 0.91 | LMNA (0.50) | LMNATDP1GAAPSMB5RECQL | |
| SCHEMBL1953631 | 0.91 | LMNA (0.50) | LMNATDP1GAAPSMB5RECQL | |
| SCHEMBL9829322 | 0.86 | NAAA (0.45) | PADI1PADI4HDAC8HDAC6LMNA | |
| SCHEMBL9829324 | 0.86 | NAAA (0.45) | PADI1PADI4HDAC8HDAC6LMNA | |
| SCHEMBL10669991 | 0.84 | LMNA (0.43) | PADI1PADI4LMNANAAATDP1 | |
| SCHEMBL10669986 | 0.84 | LMNA (0.43) | PADI1PADI4LMNANAAATDP1 | |
| SCHEMBL2795524 | 0.84 | HDAC8 (0.45) | PADI1PADI4HDAC8HDAC6LMNA | |
| SCHEMBL2794690 | 0.84 | HDAC8 (0.45) | PADI1PADI4HDAC8HDAC6LMNA | |
| SCHEMBL2797000 | 0.84 | HDAC8 (0.45) | PADI1PADI4HDAC8HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878708-B2 | Imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | CYP4F3, CYP4F2, CYP3A7 | PADI1 2595/4885PADI4 2971/4885HDAC8 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.